Abstract
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / blood supply
-
Carcinoma, Non-Small-Cell Lung / therapy
-
Clinical Trials as Topic
-
ErbB Receptors / antagonists & inhibitors
-
Humans
-
Lung Neoplasms / blood supply*
-
Lung Neoplasms / therapy*
-
Neovascularization, Pathologic
-
Piperidines / therapeutic use
-
Quinazolines / therapeutic use
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Piperidines
-
Quinazolines
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
ErbB Receptors
-
Receptors, Vascular Endothelial Growth Factor
-
vandetanib